Billion-Dollar Biotech Partnership
Novo Nordisk signs a $1.3 billion deal for Nanexa drug delivery technology.
Anonymous
Key Points
1
Nanexa’s PharmaShell is specifically described as an atomic layer deposition technology, adding detail to how the drug-delivery platform is made.
2
Nanexa shares rose from Thursday’s close of 5.93 kronor to as high as 15.50 kronor in early Stockholm trading.
3
In early Friday trading, Nanexa shares were up around 122% and had reached their highest level in more than five years.
Novo Nordisk agreed to pay Swedish drug company Nanexa up to €1.17 billion ($1.3 billion) for exclusive rights to its PharmaShell technology, which controls how medicines release in the body. IBTimes reports the deal targets long-acting injections for obesity, type 2 diabetes, and heart disease — potentially given monthly or quarterly instead of daily. Nanexa's stock soared more than 100% on the announcement, hitting its highest level in over five years.
How PharmaShell Coats and Sustains Drug Release
PharmaShell uses atomic layer deposition — a precise coating method that wraps individual drug particles in an extremely thin shell. Vyre Business News Global explains the shell dissolves slowly, controlling when and how long medicines work inside the body. This technology enables Novo to develop injections that last weeks or months instead of requiring daily doses.
Nanexa Earns Up to €615 Million in Upfront Payments
Under the deal, Nanexa receives €615 million in upfront, development, and regulatory milestone payments. The Pharma Letter reports the company also qualifies for additional sales-based milestones and low single-digit royalties on global sales. Novo Nordisk leads all development and commercialization efforts for up to five programs across obesity and cardiometabolic diseases.
Nanexa Stock Doubles in Heavy Trading
KSL reports Nanexa shares jumped from Thursday's close of 5.93 kronor to as high as 15.50 kronor in early Friday trading — a gain of 122%. The stock reached its highest price in more than five years following the announcement. The deal signals major confidence in long-acting injectable technology for treating chronic diseases like obesity and diabetes.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
22
Articles
100
Reach
122
A
AnonymousAuthor
